Assignee
LEK PHARMACEUTICALS
SI·57 granted patents·43 pending applications·345 citations·filing 1999–2022
Top patents by PatentIndex Score
100 records- 0191US6531507B1Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the sameLEK PHARMACEUTICALS·Filed 2000·Granted Mar 11, 2003·47 cites·26 claims
- 0290US8053444B2Sirolimus formulationLEK PHARMACEUTICALS·Filed 2008·Granted Nov 8, 2011·20 cites·7 claims
- 0389US6583295B1Salts of HMG-CoA reductase inhibitorsLEK PHARMACEUTICALS·Filed 1999·Granted Jun 24, 2003·32 cites·44 claims
- 0488US6613916B2Process for the preparation of amorphous atorvastatinLEK PHARMACEUTICALS·Filed 2000·Granted Sep 2, 2003·30 cites·14 claims
- 0587US7485322B2Modified release pharmaceutical compositionLEK PHARMACEUTICALS·Filed 2003·Granted Feb 3, 2009·29 cites·44 claims
- 0684US6838566B2Salts of HMG-CoA reductase inhibitorsLEK PHARMACEUTICALS·Filed 2002·Granted Jan 4, 2005·10 cites·48 claims
- 0784US6740775B1Crystalline sodium salt of pravastatinLEK PHARMACEUTICALS·Filed 2003·Granted May 25, 2004·15 cites·20 claims
- 0882US7030151B2Atorvastatin calcium in a pharmaceutical form composition thereof and pharmaceutical formulation comprising atorvastatin calciumLEK PHARMACEUTICALS·Filed 2002·Granted Apr 18, 2006·39 cites·18 claims
- 0982US6806290B2Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the sameLEK PHARMACEUTICALS·Filed 2002·Granted Oct 19, 2004·14 cites·43 claims
- 1081US6891047B2Process for the preparation of amorphous atorvastatinLEK PHARMACEUTICALS·Filed 2003·Granted May 10, 2005·14 cites·16 claims
- 1178US9732053B21-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline formLEK PHARMACEUTICALS·Filed 2014·Granted Aug 15, 2017·2 cites·14 claims
- 1278US9493409B2Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazineLEK PHARMACEUTICALS·Filed 2014·Granted Nov 15, 2016·3 cites·4 claims
- 1378US8354530B2Process for the synthesis of rosuvastatin calciumLEK PHARMACEUTICALS·Filed 2006·Granted Jan 15, 2013·4 cites·16 claims
- 1475US9284320B2Ticagrelor adducts with divalent metal saltsLEK PHARMACEUTICALS·Filed 2013·Granted Mar 15, 2016·2 cites·9 claims
- 1572US7906109B2Pharmaceutical composition comprising an active principal and sulphobetaineLEK PHARMACEUTICALS·Filed 2004·Granted Mar 15, 2011·7 cites·11 claims
- 1672US6984399B2Solid pharmaceutical formulation containing lovastatin and simvastatin respectively, and its preparationLEK PHARMACEUTICALS·Filed 2003·Granted Jan 10, 2006·5 cites·9 claims
- 1771US6696086B1Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparationLEK PHARMACEUTICALS·Filed 2000·Granted Feb 24, 2004·5 cites·14 claims
- 1869US9388188B2Synthetic route for the preparation of β-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compoundsLEK PHARMACEUTICALS·Filed 2013·Granted Jul 12, 2016·2 cites·11 claims
- 1968US7655437B2Synthetic gene coding for human granulocyte-colony stimulating factor for the expression in E. coliLEK PHARMACEUTICALS·Filed 2003·Granted Feb 2, 2010·9 cites·13 claims
- 2066US6680341B1Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitorLEK PHARMACEUTICALS·Filed 1999·Granted Jan 20, 2004·19 cites·39 claims
- 2165US9944599B2Processes for the preparation of beta-aminosulfone compoundsLEK PHARMACEUTICALS·Filed 2015·Granted Apr 17, 2018·1 cites·10 claims
- 2265US7141602B2Process for obtaining HMG-CoA reductase inhibitors of high purityLEK PHARMACEUTICALS·Filed 2003·Granted Nov 28, 2006·1 cites·5 claims
- 2364US2011136883A1Granulation of active pharmaceutical ingredientsLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 2463US2010056605A1Oxidative degradation products of atorvastatin calciumLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 2563US2024424059A1Formulations for VEGF Receptor Fusion ProteinsLEK PHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 2662US9453030B2Oxidative degradation products of atrovastatin calciumLEK PHARMACEUTICALS·Filed 2014·Granted Sep 27, 2016·0 cites·9 claims
- 2761US7585496B2Stable pharmaceutical composition granulocyte-colony stimulating factorLEK PHARMACEUTICALS·Filed 2003·Granted Sep 8, 2009·2 cites·19 claims
- 2860US2008188552A1New salts of HMG-CoA reductase inhibitorsLEK PHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 2960US2011008439A1Duloxetin compositionLEK PHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 3060US2009264497A1Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitorLEK PHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 3159US6695969B1Process for obtaining HMG-CoA reductase inhibitors of high purityLEK PHARMACEUTICALS·Filed 1999·Granted Feb 24, 2004·18 cites·26 claims
- 3257US7534870B2Stable pharmaceutical composition comprising erythropoietinLEK PHARMACEUTICALS·Filed 2003·Granted May 19, 2009·3 cites·18 claims
- 3356US9622976B2Pharmaceutical compositionLEK PHARMACEUTICALS·Filed 2014·Granted Apr 18, 2017·0 cites·7 claims
- 3456US2011112160A1Tablet comprising eprosartan mesylateLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 3556US2008299193A1Pharmaceutical composition comprising eszopliconeLEK PHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 3656US2023137216A1Stabilization of Pharmaceutical Compositions Comprising PolysorbateLEK PHARMACEUTICALS·Filed 2021·Application pending·0 cites
- 3755US9907757B2Coated particles and pharmaceutical dosage formsLEK PHARMACEUTICALS·Filed 2015·Granted Mar 6, 2018·0 cites·8 claims
- 3855US2011068497A1Preparation of nanoparticles by using a vibrating nozzle deviceLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 3954US8044086B2Oxidative degradation products of atorvastatin calciumLEK PHARMACEUTICALS·Filed 2005·Granted Oct 25, 2011·0 cites·3 claims
- 4054US7875723B2S-omeprazole magnesiumLEK PHARMACEUTICALS·Filed 2009·Granted Jan 25, 2011·0 cites·10 claims
- 4154US7671215B2Process for the preparation of compounds having an ace inhibitory actionLEK PHARMACEUTICALS·Filed 2004·Granted Mar 2, 2010·1 cites·6 claims
- 4254US6509479B1Process for the removal of a silyloxy protecting group from 4-silyloxy-tetrahydro-pyran-2-onesLEK PHARMACEUTICALS·Filed 2000·Granted Jan 21, 2003·1 cites·13 claims
- 4354US2011262497A1Novel ezetimibe formulationsLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 4454US2010305087A1Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubilityLEK PHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 4553US10323056B2Crystalline hydrates of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzeneLEK PHARMACEUTICALS·Filed 2014·Granted Jun 18, 2019·0 cites·15 claims
- 4652US9562082B2Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) contentLEK PHARMACEUTICALS·Filed 2014·Granted Feb 7, 2017·0 cites·17 claims
- 4752US7560474B2Derivatives of pyridilethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, process for their preparation and pharmaceutical compositions containing themLEK PHARMACEUTICALS·Filed 2003·Granted Jul 14, 2009·2 cites·10 claims
- 4852US7271269B2Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methodsLEK PHARMACEUTICALS·Filed 2004·Granted Sep 18, 2007·1 cites·5 claims
- 4952US2010120868A1Process For Preparing Solid Dosage Forms of Rosiglitazone MaleateLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 5051US9428562B2Production of glycoproteins with low N-glycolylneuraminic acid (NEU5GC) contentLEK PHARMACEUTICALS·Filed 2014·Granted Aug 30, 2016·0 cites·14 claims
Showing the top 50 of 100 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →